FIELD: medicine, gastroenterology, pharmacology.
SUBSTANCE: invention relates to compositions comprising a substance possessing regulating activity, for example, inhibition of proliferation of cells expressing AILIM, for suppression of onset of intestine inflammatory diseases, in particular Crohn's disease, and colitis. Invention provides enhancing the therapeutic effect.
EFFECT: valuable medicinal properties of agents.
10 cl, 12 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
| AGENTS SUPPRESSING REJECTION OF TRANSPLANT | 2002 |
|
RU2263512C2 |
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| PROPHYLACTIC OR THERAPEUTIC AGENT FOR TREATING INFLAMMATORY INTESTINAL DISEASES CONTAINING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT | 1999 |
|
RU2195960C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| RECOMBINANT ANTIBODY AGAINST CD4 FOR HUMAN THERAPY | 1996 |
|
RU2232773C2 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
| METHOD OF TREATING INFLAMMATION IN NEURONAL TISSUE WITH USING MONOCLONAL ANTIBODY AND ITS BINDING FRAGMENT | 2007 |
|
RU2565391C2 |
